Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 5, 1999, Pages 964-968

  Passalacqua, Giovanni ^a   Albano, Monica ^a   Riccio, Annamaria ^a   Fregonese, Laura ^a   Puccinelli, Paola ^b   Parmiani, Silvano ^b   Canonica, Giorgio Walter ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b ALK Abello Group   (Italy)

^c Allergy and Respiratory Diseases   (Italy)

Author keywords

Allergen specific nasal challenge; Allergic inflammation; Intercellular adhesion molecule 1; Sublingual swallow immunotherapy

Indexed keywords

ALLERGEN; INTERCELLULAR ADHESION MOLECULE 1;

ADULT; ALLERGY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; FEMALE; HUMAN; IMMUNOTHERAPY; INFLAMMATORY INFILTRATE; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RHINOCONJUNCTIVITIS; SEASONAL VARIATION;

EID: 0032713995     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70076-X     Document Type: Article

References (25)

1. 1. Malling HJ, Weeke B, editors. EAACI immunotherapy position paper. Allergy 1993;48:1-81.
2. 2. Bousquet J, Lockey RF, Malling HJ, editors. WHO position paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998:53(44 Suppl):20-2.
3. 3. Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, Bjorksten B, Bousquet J, Caillot D, et al. EAACI/ESPACI position paper on local immunotherapy. Allergy 1998;53:833-44.
4. 4. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol 1990;18:277-84.
5. 5. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol 1995;23:173-8.
6. 6. Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309-13.
7. 7. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in parictaria pollen induced rhinitis: a double blind study. J Invest Allergol Clin Immunol 1995;5:25-30.
8. 8. Hirsch T, Sahn M, Leupold W. Double blind placebo controlled study of sublingual immunotherapy with house dust mite extract (D pt) in children. Pediatr Allergy Immunol 1997;8:21-7.
9. 9. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629-32.
10. 10. Clavel R, Bousquet J, Andre' C. Clinical efficacy of sublingual swallow immunotherapy. a double blind placebo controlled trial of standardized five grass pollen extract in rhinitis. Allergy 1998;53:493-8.
11. 11. Vourdas D, Syrigou E, Potamianou B, et al. Double blind placebo controlled evaluation of sublingual immunotherapy with standardized olive tree pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive tree pollen sensitization. Allergy 1998;53:662-71.
12. 12. Horak F, Stubner UE, Berger U, Marks B, Toth J, Jager S. Immunotherapy with sublingual birch pollen extract: a short term double blind study. J Invest allergol Clin Imunol 1998;8:165-71.
13. 13. Holt PG. A potential vaccine strategy for asthma and allied atopic diseases during childhood. Lancet 1994;344:456-8.
14. 14. Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997;100:121-9.
15. 15. Passalacqua G, Albano M, Ruffoni S, et al. Local nasal immunotherapy to parietaria: evidence of reduction of allergic inflammation. Am J Respir Crit Care Med 1995;152:461-6.
16. 16. Giannarini L, Maggi E. Decrease of allergen-specific T cell response induced by nasal immunotherapy. Clin Exp Allergy 1998;28:863-6.
17. 17. Ciprandi G, Pronzato C, Ricca V, Passalacqua G, Bagnasco M, Canonica GW. Allergen specific challenge induces ICAMI expression on nasal epithelial cells in allergic subjects: relationships with early and late phase events. Am Rev Respir Dis 1994;150:1653-9.
18. 18. Carreira J, Rubio M, Herrero T, et al. Collaborative clinical assay of the biological potency of allergen skin test extracts. Clin Allergy 1984;14:503-7.
19. 19. Carreira, Lombardero M, Ventas P. New developments in in vitro methods. Quantification of clinically relevant allergens in mass units. Arbeiten aus dem Paul Ehrlich Institut. Stuttgart: Gustav Fischer Verlag; 1994.
20. 20. Cordell JL, Falini B, Erber WN, et al, Immunoenzymatic labelling of monoclonal antibodies using immunocomplexes of alkaline phosphatase and monoclonal anti alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-45.
21. 21. Hamid Q, Schotman E, Jacobson M, Walker S, Durham S. Increases in interleukin 12 messenger RNA+ cells accompany inhibition of allergen induced late skin responses following successfull grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-60.
22. 22. Rak S, Hakanson L, Venge P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity. J Allergy Clin Immunol 1990;86:706-11.
23. 23. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-30.
24. 24. Ciprandi G, Passalacqua G, Azzarone B, Bagnasco M, Canonica GW. Molecular events in allergic inflammatiom: expression of adhesion molecules and their modulation. In: Asthma and allergic diseases. Marone G, Austen KF, Holgate ST, et al, editors. San Diego: Academic Press; 1998. p. 309-19.
25. 25. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999. In press.